Opus Genetics holder cuts stake below 5%
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary
Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. filed Amendment No. 3 to their Schedule 13D for Opus Genetics, Inc. The filing reflects a reduced position of 3,792,171 shares of common stock, representing 4.66% of the company’s outstanding shares.
This change results from selling Opus Genetics common stock on May 18, 2026. Based on 81,395,539 shares outstanding as of May 7, 2026, the reporting persons now hold less than five percent and characterize this amendment as an exit filing ending their Schedule 13D reporting obligations.
Key Figures
Beneficial ownership: 3,792,171 shares
Ownership percentage: 4.66%
Shares outstanding: 81,395,539 shares
+2 more
5 metrics
Beneficial ownership
3,792,171 shares
Foundation Fighting Blindness entities’ Opus Genetics common stock
Ownership percentage
4.66%
Percent of Opus Genetics common stock class represented
Shares outstanding
81,395,539 shares
Opus Genetics common stock outstanding as of May 7, 2026
Event date
May 18, 2026
Date of share sale that changed beneficial ownership
Amendment number
Amendment No. 3
Latest amendment to Schedule 13D for Opus Genetics
Key Terms
beneficial ownership, Schedule 13D, Agreement and Plan of Merger, Series A Non-Voting Convertible Preferred Stock, +1 more
5 terms
beneficial ownership financial
"This Amendment No. 3 on is being filed to show the change in percentage of beneficial ownership held by the Reporting Persons"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Schedule 13D regulatory
"This Amendment No. 3 on amends the statement on , dated October 29, 2024, which relates to the Common Stock of the Issuer, filed by the Reporting Persons."
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
Agreement and Plan of Merger regulatory
"Exhibit 1 - Agreement and Plan of Merger, dated October 22, 2024, by an among Ocuphire Pharma, Inc., Orange Merger Sub I, Inc., Orange Merger Sub II, LLC, and Opus Genetics Inc."
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Series A Non-Voting Convertible Preferred Stock financial
"Exhibit 2 - Certificate of Designations of the Series A Non-Voting Convertible Preferred Stock"
Series A non-voting convertible preferred stock is an early-round ownership share that gives holders priority over common shareholders for payouts and protections, but does not grant voting control. It can be exchanged later for common shares—like a coupon that can be turned into regular stock—allowing investors to share in upside while limiting immediate influence on company decisions; this affects potential returns, dilution for other shareholders, and the balance of control in future financing or sale events.
Registration Rights Agreement regulatory
"Exhibit 4 - Form of Registration Rights Agreement (included as Exhibit F to the Agreement and Plan of Merger)"
A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the latest Schedule 13D/A filing reveal about IRD’s Opus Genetics stake?
The filing shows Foundation Fighting Blindness entities now beneficially own 3,792,171 Opus Genetics shares, or 4.66% of outstanding common stock. This follows share sales on May 18, 2026, reducing their holdings below the 5% reporting threshold.
Why is this Schedule 13D/A amendment considered an exit filing for IRD?
It is an exit filing because the reporting persons’ beneficial ownership in Opus Genetics fell below 5%, to 4.66%. Once below this threshold, they no longer have ongoing Schedule 13D reporting obligations for this position, absent future increases above 5%.
Which entities associated with IRD are the reporting persons in this Schedule 13D/A?
The reporting persons are Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. Both report shared voting and dispositive power over 3,792,171 Opus Genetics common shares, reflecting coordinated beneficial ownership of the same block.
What transaction triggered the updated beneficial ownership for IRD in Opus Genetics?
The updated ownership stems from selling Opus Genetics common stock on May 18, 2026. These sales reduced the reporting persons’ holdings to 3,792,171 shares. A related Form 4 filed on May 20, 2026 provides additional transaction details and is incorporated by reference.
AI-generated analysis. How Rhea-AI works. Not financial advice.
